{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-22-000002","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2022-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.429792+00:00","generated_at":"2026-06-27T21:04:36.758131+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Tarsus appoints Elizabeth Yeu, M.D. to Board of Directors","bullets":["Dr. Yeu appointed as Class II director effective Dec 31, 2021; term expires at 2022 annual meeting.","She continues as Chief Medical Advisor under consulting agreement with $240k annual cash compensation.","Dr. Yeu brings over 20 years of eye care experience; will serve on Science and Technology Committee.","Appointment comes as Tarsus nears potential commercialization of lead candidate TP-03 for Demodex blepharitis.","No arrangements or understandings for her election; standard indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-22-000002","json":"https://secwatch.observer/filing/0001819790-22-000002.json","markdown":"https://secwatch.observer/filing/0001819790-22-000002.md","text":"https://secwatch.observer/filing/0001819790-22-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000002/0001819790-22-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000002/tars-20211231.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T21:04:36.758131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8978a84987","claim":"Elizabeth Yeu-Lin, M.D. was appointed as Director at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"appointed Elizabeth Yeu-Lin, M.D. to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000002/0001819790-22-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}